Key Takeaways
- • Andrew Left, founder of Citron Research, was convicted on one count of securities fraud and 12 counts of securities fraud in federal court (Central District of California), with IGC Pharma identified as a targeted company in the alleged scheme.
- • IGC Pharma is actively evaluating potential civil remedies and damages recovery related to a 2018 short campaign allegedly orchestrated by Left and a hedge fund partner against the company when it was known as India Globalization Capital, Inc.
- • The indictment alleges the short campaign occurred in October 2018 and raises questions about its impact on IGC shareholders; CEO Ram Mukunda stated the company is reviewing "whether IGC has recoverable damages and what remedies may be available."
- • IGC Pharma is a clinical-stage biotechnology company advancing a Phase 2 Alzheimer's disease program, operating under its current NYSE American listing (ticker: IGC).
Summary
IGC Pharma announced on July 29, 2026, that it is evaluating potential civil recovery options following the federal conviction of Andrew Left, founder of Citron Research, on securities fraud charges. According to the U.S. Attorney's Office for the Central District of California, Left was found guilty of one count of engaging in a securities fraud scheme and 12 counts of securities fraud in United States v. Andrew Left (No. 2:24-CR-456). The verdict has renewed focus on a 2018 short campaign that targeted IGC when the company operated under its former name, India Globalization Capital, Inc.
The federal indictment alleged that in October 2018, Left and an unnamed hedge fund coordinated a short campaign against IGC. IGC management now believes the guilty verdict and public record evidence support a serious review of the conduct surrounding that campaign and its shareholder impact. CEO Ram Mukunda stated that shareholders have questioned the 2018 campaign for years and that the company is "evaluating whether IGC has recoverable damages and what remedies may be available to protect the interests of the Company and its shareholders."
The conviction provides potential legal grounds for civil litigation. IGC, currently a clinical-stage biotechnology company focused on Alzheimer's disease therapeutics, plans to examine available legal remedies and the strength of potential damage claims arising from the alleged short campaign. The company's evaluation suggests that shareholders may have grounds to pursue recovery for losses sustained during the 2018 short manipulation, with the federal conviction now establishing a factual record regarding the fraudulent scheme.
The federal indictment alleged that in October 2018, Left and an unnamed hedge fund coordinated a short campaign against IGC. IGC management now believes the guilty verdict and public record evidence support a serious review of the conduct surrounding that campaign and its shareholder impact. CEO Ram Mukunda stated that shareholders have questioned the 2018 campaign for years and that the company is "evaluating whether IGC has recoverable damages and what remedies may be available to protect the interests of the Company and its shareholders."
The conviction provides potential legal grounds for civil litigation. IGC, currently a clinical-stage biotechnology company focused on Alzheimer's disease therapeutics, plans to examine available legal remedies and the strength of potential damage claims arising from the alleged short campaign. The company's evaluation suggests that shareholders may have grounds to pursue recovery for losses sustained during the 2018 short manipulation, with the federal conviction now establishing a factual record regarding the fraudulent scheme.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.